Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Report library

Report library


loader
  • Sort by Product ID
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Respiratory Syncytial Virus (RSV) Prevention KOL Interview

    Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

    December 22, 2021
    Find out more
  • Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #2

    Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #2

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

    December 22, 2021
    Find out more
  • Biomedtracker Meddevice Tracker Early 2022 Outlook Report

    $4,750.00

    Biomedtracker Meddevice Tracker Early 2022 Outlook Report

    February 8, 2022
    Find out more
  • Atopic Dermatitis and Psoriasis KOL Interview

    Atopic Dermatitis and Psoriasis KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

    November 18, 2021
    Find out more
  • Bone Grafts and Substitutes Market

    Bone Grafts and Substitutes

    $4,750.00

    This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global market for bone grafts and substitutes. Product segments covered by this report include allografts and synthetic bone substitutes, growth factors, and cellular bone matrices.

    February 15, 2022
    Find out more
  • Drug Delivery: Injection Devices

    Drug Delivery: Injection Devices

    $4,750.00

    Despite its relative invasiveness and technological maturity, instrument-based injection of pharmaceutical preparations is commonly regarded as the most accurate, effective, reliable, and reproducible method of therapeutic drug and fluid delivery. In 2021, combined sales of the injection devices covered by this report totaled nearly $5.7bn.

    March 15, 2022
    Find out more
  • Atopic Dermatitis and Psoriasis KOL Interview – US, Southeast

    Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

    November 18, 2021
    Find out more
  • Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

    Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

    November 18, 2021
    Find out more
  • Atopic Dermatitis and Psoriasis KOL Interview – US, South

    Atopic Dermatitis and Psoriasis KOL Interview – US, South

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

    November 18, 2021
    Find out more
  • Prostate Cancer KOL Interview – US, Northeast #2

    Prostate Cancer KOL Interview – US, Northeast #1

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, and Lutetium 177Lu-PSMA-617.

    February 9, 2022
    Find out more
  • Prostate Cancer KOL Interview – US, Northeast #2

    Prostate Cancer KOL Interview – US, Northeast #2

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, Lutetium 177Lu-PSMA-617, and CAN-2409.

    February 9, 2022
    Find out more
  • Prostate Cancer KOL Interview – UK #1

    Prostate Cancer KOL Interview – UK #1

    $599.00

    A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.

    February 9, 2022
    Find out more
  • Prostate Cancer KOL Interview – UK #2

    Prostate Cancer KOL Interview – UK #2

    $599.00

    A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.

    February 9, 2022
    Find out more
  • Acute Myeloid Leukemia

    Acute Myeloid Leukemia (AML) KOL Interview – US, South

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

    March 14, 2022
    Find out more
  • Acute Myeloid Leukemia (AML) KOL Interview – Italy

    Acute Myeloid Leukemia (AML) KOL Interview – Italy

    $599.00

    An interview with an Italian key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Onureg, Idhifa, Tibsovo, magrolimab, crenolanib, gilteritinib, and Iomab-B.

    March 14, 2022
    Find out more
Page 84 of 85
Page 84 of 85«‹82838485›
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top